Targets › NPR2
2 programs from 2 companies in 10 trials: 8 Phase 2, 2 Phase 3; Other, Metabolic and endocrine; next expected readout Mar 2027.
Receptor for the C-type natriuretic peptide NPPC/CNP hormone. Has guanylate cyclase activity upon binding of its ligand. (UniProt, P20594)
Open in Phaseline: the race on NPR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical | Vosoritide Atrial natriuretic peptide receptor B binding agent | NPR2 | Phase 3 | Hypochondroplasia; Achondroplasia; Noonan Syndrome; Idiopathic Short Stature … | Mar 2027 |
| Ascendis Pharma Growth Disorders | Navepegritide C-type natriuretic peptide (CNP) analog | NPR2 | Phase 2 | Achondroplasia | Nov 2027 |
Achondroplasia (5) Hypochondroplasia (2) Noonan Syndrome (1) Idiopathic Short Stature (1) Short Stature (1)
protein or peptide (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.